Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity
A. Ugarte(National University of Northwestern Buenos Aires), Guillermo Ruiz‐Irastorza(BioCruces Health research Institute), N. Agesta(Hospital de Cruces), Norberto Ortego‐Centeno, Aleida Martínez Zapico(BioCruces Health research Institute), Rafael Ríos(Hospital Universitario 12 De Octubre), Sabrina Porta(A. O. Ordine Mauriziano di Torino)
Cited by 30
Related Papers
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
|Journal of Clinical Oncology|2019|279
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
|Blood|2019|218
A Randomized Trial of Intravenous Amino Acids for Kidney Protection
|New England Journal of Medicine|2024|178
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
|Blood|2020|156
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus
|Human Molecular Genetics|2008|124